Session: MON 776-795-Cardiometabolic Risk & Vascular Biology
Poster Board MON-793
The authors assessed the evolution of glycemic control, DM2 therapy and its effects on weight on 115 DM2 patients on the first 3 years of follow up at an Endocrinology Center. One-way ANOVA or paired t-test were used to study normally distributed variables.
At baseline, median duration of diabetes was 7 years, mean age 60,5 years (+/-10), HbA1c 9,4% (+/-2,3) and weight 75,7 Kg (+/-17). Self monitoring of blood glucose (SMBG) was performed adequately by 48.7% of patients. Initial therapy consisted in lifestyle measures only in 4,3%, oral agents (OA) without insulin in 60% (metformin plus sulfonylurea in 32,9%, sulfonylurea in 24,4% and metformin in 22%) and insulin in 27,8% (70% with NPH, 23,3% with mixture and 6,6% with glargine).
At the end of the third year, SMBG was performed adequately by 73% (p<0,01). No patient stayed on lifestyle measures only; there was a decrease in OA without insulin to 28.7% (metformin in 35%, metformin with ddp4 inhibitor in 21% and metformine plus sulfonylurea plus dpp4 inhibitor in 16,7%), and an increase in insulin containing therapies to 71,3% (44,8% with NPH, 33,8% with mixture, 15% with glargine and 7,5% with detemir) (p<0,05).
The HbA1c decreased to 7,4% (+/-1,1) (p<0,001) and weight increased to 81,5 Kg (+/-17,2) (p<0,001). During this period, no major hypoglycemic events were observed. The magnitude of improvements in HbA1c was different depending on treatment groups: patients who stayed on OA improved 1%, patients who were kept on insulin improved 2,5% and patients who switched to insulin improved 3,2% (p<0.05).
There was a significant improvement in SMBG and glycemic control over 3 years of follow up at the Endocrinology Center. This occurred along with an increase in the use of insulin based therapies. Although an average increase in weight of 1,9 Kg/year was observed, there was no significant increase in major hypoglycemic events.
Nothing to Disclose: TLN, HVL, BDP, AV, ACM, IM, MCC, LR, JP
*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm
See more of: Abstracts - Orals, Featured Poster Presentations, and Posters